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Background: Seasonal influenza causes significant morbidity and mortality, and represents
a recurring financial burden for community- and hospital-based treatment. Nosocomial
outbreaks exacerbate the impact of influenza. Rapid diagnosis of influenza has been shown
to reduce transmission. However, point-of-care testing (POCT) in emergency departments
and prudent direction of patients with the virus to reduce hospital-acquired infection
(HAI) have not been evaluated widely.
Aim: To assess performance characteristics of the Abbott ID NOW Influenza A & B 2
system, impact on incidence of hospital-acquired influenza, and admission rate ratio for
patients who have POCT compared with laboratory testing. POCT was introduced in the
2018e2019 influenza season. Data from then were compared with preceding and sub-
sequent seasons.
Methods: Records of POCT and laboratory testing for the 2017e2018, 2018e2019, and
2019e2020 influenza seasons were analysed. Sensitivity and specificity of POCT were
compared pairwise with Xpert Flu A/B/RSV. Patient admission rates and time of waiting for
admission were compared.
Findings: Compared to laboratory assay, POCT demonstrated sensitivity of 90.6% (95%
confidence interval (CI): 78.6e96.5) and specificity of 99.2% (95.2e100) for influenza A,
with 51.4% and 41.9% reductions in numbers of HAIs observed in the two seasons when
POCT was available, respectively. The admission rate ratio for influenza cases diagnosed
by POCT compared with laboratory diagnosis was 0.72 (95% CI: 0.53e0.97; P ¼ 0.031).
Conclusion: POCT for influenza appears a feasible strategy for testing of patients during
peak influenza virus season, with potential to reduce HAI. The relatively rapid turnaround
time may also benefit clinical management of patients presenting at emergency depart-
ments with suspected influenza.Medicine, University of
-0430739.
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Seasonal influenza causes significant morbidity and mortal-
ity yearly. Its burden with respect to healthcare costs is sig-
nificant. In the EU, it is estimated that the economic impact of
seasonal influenza ranges between V6 billion and V14 billion
annually [1]. Yan et al. estimated that, in the USA, yearly
seasonal influenza costs between US$2 and 5.8 billion in
healthcare costs alone [2]. Notably, costs are elevated when
cases involve children, and when influenza B is prevalent [2,3].
Associated care represents a considerable recurring financial
burden with respect to both community- and hospital-based
healthcare. However, in the latter case, nosocomial out-
breaks exacerbate the impact of influenza on hospital man-
agement and clinical care. For example, Sendi et al. reported a
small outbreak involving 18 patients in a rehabilitation unit
costing $112,131 in direct and indirect expenses, including
staff illness [4]. Similarly, Marbus et al. estimated the cost of
hospitalization in the Netherlands for each adult influenza
patient to be between V4,934 and V10,665 [5].
Prior to advent of rapid influenza diagnostic testing (RIDT),
turnaround time for influenza testing could be as long as days
due to referring for centralized laboratories where local testing
is unavailable. In that context, Alveraz-Lerma et al. reported
increasing mortality and poorer outcomes for critically ill
patients associated directly with delayed influenza A (H1N1)
diagnosis [6]. It is, therefore, reasonable to state that as RIDT is
now available commercially and relatively inexpensively, rapid
diagnostic testing for influenza has potential to support
appropriate bed management of patients, both in isolation and
cohort areas, and to enable optimized patient care.
There are several commercial assays available for point-of-
care testing (POCT) that allow rapid turnaround of results. The
Abbott ID NOW Influenza A & B 2 (previously Alere i Influenza
AþB) is an isothermic multiplex polymerase chain reaction
(PCR) device that detects influenza A and B. Although the
sensitivity and specificity are slightly lower than other real-
time PCR assays, ease of use makes it an ideal POCT or near-
patient care device with results available in 20 min [7,8].
Unfortunately, despite perceived benefits of POCT for influ-
enza, many studies report conflicting results regarding impact
on clinical care. A meta-analysis of the clinical utility of POCT
for influenza in the ambulatory setting showed no effect on
admissions or antibiotic prescribing, but demonstrated a
reduction in other investigations ordered and increased anti-
viral prescribing [9]. Conversely, another systematic review
on the impact of POCT for patients with acute respiratory tract
infection reported reduced antibiotic prescribing in influenza-
positive patients [10].
Few studies focus on the use of POCT for adult patients in
the emergency department (ED) setting. However, both Trab-
bitoni et al. and Lankelma et al. reported reduction in admis-
sions of patients tested with point-of-care technology for
influenza [11,12]. The former also reported a reduction in time
spent in the ED. To our knowledge no study has looked at the
impact of ED POCT in reducing healthcare-associated influenzacases specifically. Therefore, in this study, our objective was to
understand the influence of introducing POCT on ED use of
isolation facilities within the department during peak influenza
seasons. Particular emphasis was placed on potential reduction
in acquisition of influenza in the ED and assistance with patient
flow or treatment. Molecular technologies are also becoming
increasingly pivotal in addressing diagnostic conundrums in
infectious diseases and actionable case management [13,14].
We have previously described the role of timely diagnosis of
infectious pathogens, in conjunction with appropriate infec-
tion control measures, in reducing transmission of micro-
organisms and curtailing of potential outbreaks [15,16].
Therefore, in this study, we continued this focus in attempting
to determine performance characteristics of POCT in compar-
ison with our laboratory facilities.
Methods
Setting
The University Limerick Hospital Group (ULHG) comprises
six acute hospitals including one tertiary referral hospital,
three level-two hospitals with acute medical assessment units,
one maternity hospital, and one orthopaedic hospital.
The ED in University Hospital Limerick (UHL) serves a
population total of w473,000. The UHL ED is the only one
within the hospital group and is the referral point for the
region. In 2019, the ED attendances were 71,315 with an
average of 195 presentations per day [17]. The ED has 24
single-room isolation facilities and six single resuscitation
bays. Despite being below the national benchmark for the
average length of stay in medical inpatients (5.3 vs 6.3
days), due to bed capacity issues it is subject to prolonged
delays in transferring patients to ward beds [18]. Impor-
tantly, and relevant to this study, influenza vaccine uptake
for UHL’s healthcare staff was 41.5%, 41.0%, and 40.1% for
the 2017e2018, 2018e2019, and 2019e2020 influenza sea-
sons, respectively [19e21]. From January 2018, a POCT
assay using the Alere i Influenza AþB (renamed Abbott ID
NOW Influenza A & B 2 for the 2019e2020 influenza
season) was placed into the emergency department of
UHL.
Ethical approval
This study was approved by the Research Ethics Committee
of University Limerick Hospital Group, Limerick, Ireland.
Patient data
Data for all three influenza seasons were collected ret-
rospectively from multiple sources; however, all patient
data were anonymized in compliance with the General Data
Protection Regulation. Results of POCT influenza inves-
tigations were collated from stored paper records for
2018e2019 and 2019e2020. Paper records were used during
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software to interface the POCT device directly with the
laboratory information management system (DXC/iLAB).
Paper records were used for both recording and notification
purposes to the Irish Department of Public Health, and
hospital infection prevention and control teams. Where
available, comparative results and laboratory-derived
results were collated using the LIM system (DXC/iLAB).
Data specific to patient episodes and admissions were
identified and retrieved using the hospital’s electronic
Inpatient Manager System (iPMS) as were ED data pertaining
to initial patient presentation, admission, and bed waiting
times. Durations of peak influenza seasons were determined
using Irish national surveillance data.
Adult patients (defined as aged 16 years) who had under-
taken a POCT for influenza, or who tested positive for influenza
using laboratory assays, during the three influenza seasonswere
included in the analyses. The criteria for POCT in the ED are
described in Box 1. A key outcomewas the number of confirmed
healthcare-associated influenza cases that occurred during the
peak of each influenza season. All patients with a laboratory-
confirmed influenza result on a nasopharyngeal swab collected
after 48 h of admission were defined as healthcare-associated
influenza cases. This definition is in accordance with the Euro-
pean Centre for Disease Prevention and Control (ECDC) defi-
nition for healthcare-associated infections [22].
A further outcome was the admission rate ratio for patients
who received a POCT influenza result versus a laboratory-based
result. To determine this, admission numbers for all positive
influenza cases with a POCT result were compared with the
admission numbers for all positive influenza cases determined
using a laboratory-based assay. The impact of POCT for influ-
enza on average admissions via the ED, and average time spent
in the ED for those admitted patientswhile awaiting award bed,
were analysed for each of the three influenza seasons.
Test performance characteristics
Performance characteristics of the Abbott ID NOW Influ-
enza A & B 2 were explored. The sensitivity, specificity, positiveBox 1
Patient testing criteria for use of emergency department point-of-
care testing (POCT) for influenza






e Shortness of breath
e Headache
e Myalgia
POCT for influenza to be considered in patients with
influenza like-illness. Those patients should be isolated
and/or asked to wear a mask pending clinical decision or
test result.
POCT for influenza is not recommended for patients who
do not have influenza-like illness.predictive value and negative predictive value were calculated
for all POCT results sent for duplicate testing using a
laboratory-based assay. For clarity, training was provided by
the manufacturer to all ED clinicians and nurses for 6 weeks
prior to the installation of the POCT device at the beginning of
each influenza season. The POCT device was available for
routine clinical use from January 15th, 2019 to May 9th, 2019
and November 28th, 2019 to February 28th, 2020. The device
was removed at the end of the influenza season. Notably, the
decision to remove the POCT equipment in February 2020 was
due to the evolving nature of the SARS-CoV-2 situation in
Europe and the perceived limited utility of an influenza-only
assay.
Performance of the POCT, for all three seasons, involved a
single nasopharyngeal swab in UTM: Viral Transport Medium
(Copan Diagnostics, Brescia, Italy) for patients fulfilling case
criteria for influenza. Validation was performed concurrently
by comparison of POCT results with those of the Xpert Flu A/B/
RSV (Cepheid, Sunnydale, CA, USA).
During the pre-POCT influenza season of 2017e2018, the
standard of care test was the Xpert Flu A/B/RSV located in
UHL’s laboratory. However, after-hours routine testing was not
available prior to implementation of POCT due to staffing
constraints. Upon adoption of POCT, the testing process
involved collection of a nasopharyngeal swab that could be
performed by trained ED physicians or nurses, and was avail-
able 24 h, 7 days a week. During the validation period (and
afterwards if samples provided invalid or suspect results), the
same swab with the viral transport media was sent to the
laboratory for confirmatory diagnostic analysis using the Xpert
Flu A/B/RSV system. ED samples referred for in-house testing
were stored at room temperature in the laboratory and tested
upon arrival if between 08:00 and 20:00, or during the next
business day if received after 20:00. During the validation
period for the 2018e2019 season, a performance issue was
noted whereby influenza A and B were reported together, or
influenza B reported alone (as national surveillance data
showed very minimal influenza B circulating). All swabs with
such POCT results were referred for confirmatory testing. In
addition, five samples were referred for testing using the
Luminex NxTAG Respiratory Pathogen Panel (bioMérieux,
Marcy l’Etoile, France) at the Irish National Virus Reference
Laboratory (NVRL, Dublin) due to request for respiratory syn-
dromic testing in addition to influenza testing.Statistics
Analyses were performed using Microsoft Excel 2016
(V16.0); P  0.05 was considered statistically significant.Results
In Ireland, the reported peak influenza season lasted 14, 9,
and 12 weeks for the 2017e2018, 2018e2019, and 2019e2020
seasons, respectively. In the 2017e2018 season, influenza B/
Yamagata lineage and influenza A (H3N2) were the dominant
circulating strains, with lower but still significant levels of
influenza A(H1N1)pdm09 [23]. In the 2018/2019 season, there
was co-circulation of influenza A(H1N1)pdm09 and influenza
A(H3N2) with little influenza B activity (0.03% of all samples
sent to the national virus reference laboratory) [24]. At the
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was still awaited, but it was known that the season was
dominated by influenza A, with low levels of circulating influ-
enza B [25]. Influenza incidences during the 2017e2018 and
2019e2020 seasons crossed the threshold for medium intensity
prevalence levels during their peaks, but the 2018e2019 season
was defined as low intensity (according to the Irish Health
Protection Surveillance Centre) [23e25]. Our POCT and lab-
oratory results for influenza reflected the national data.
There was no significant variance in laboratory tests
requested across the three influenza seasons with 2409, 2311,
and 2430 tests requested at UHL between October and May for
2017e2018, 2018e2019, and 2019e2020, respectively. In all,
518 and 709 POCTs were performed for the 2018e2019 and
2019e2020 seasons, respectively. Table I shows data on daily
presentations, admissions, and bed waiting times for the ED for
all three influenza seasons. The 2018e2019 influenza season
had the highest daily attendance across the three influenza
seasons (mean: 199.7 per day), although admission rates were
lower than the previous season (reduction of 9.8%). Increasing
wait times (mean: 13.7, 15.93, and 17.93 h for 2017e2018,
2018e2019, 2019e2020, respectively) for a bed across the
three seasons reflects ongoing bed capacity issues in Ireland
generally and specifically the mid-West region where this study
focused.Performance characteristics
During the early phase of POCT assay implementation in the
2018/2019 influenza season there was a global performance
issue with the assay, leading to false-positive results. Prompt
recognition of this issue led to corrective actions requiring
duplicate parallel laboratory testing. Duplicate laboratory
testing was required on 25.3% (131/518) and 10.8% (77/709) of
samples in the 2018e2019 and 2019e2020 influenza seasons,
respectively. All of these tests, except for five, were performed
using Xpert Flu A/B/RSV. Those five samples were sent for
syndromic respiratory panel testing and were referred to the
national viral reference laboratory. The issue was resolved by
the manufacturer for the 2019e2020 season.
Overall, having corrected for all results reporting positive
for influenza A and B concurrently (N ¼ 15), the calculated
sensitivity for influenza A was 90.6% (95% confidence interval
(CI): 78.6e96.5), specificity was 99.2% (95.2e100), positive
predictive value was 97.8% (87.8e99.9), and negative pre-
dictive value was 96.3% (91.1e96.6). Performance character-
istics for influenza B were as follows: sensitivity 100%
(67.9e100), specificity 93.6% (88.6e96.6), positive predictive
value 50% (28.8e71.2), and negative predictive value of 100%
(97.1e100). However, only 11 confirmed influenza B cases withTable I
Average emergency department attendances, admissions, and average
Date period Attendances A
Dec 11th, 2017eMar 18th, 2018 197 (196) [57.24] 67.3
Dec 31st, 2018eMar 3rd, 2019 199.52 (198) [59.45] 60.68
Dec 2nd, 2019eFeb 23rd, 2020 187.5 (188) [54.42] 56.80
a Mean (median) [2 standard deviations].
b Further advanced statistical analysis of curve not performed but it is expairwise testing were diagnosed using POCT across the two
influenza seasons.
Healthcare-associated influenza outcomes
Upon implementation of POCT, there was a marked reduc-
tion in the number of observed healthcare-associated influenza
cases. Seventy-four cases of healthcare-associated influenza
cases were detected in 2017e2018 prior to implementation of
POCT. By contrast, there were 36 healthcare-associated influ-
enza cases during the 2018e2019 influenza season (five cases
before and 31 after POCT had been implemented), and 43 cases
for the entire 2019e2020 influenza season. This reflects a
reduction of 51.4% and 41.9% for the 2018e2019 and
2019e2020 seasons, respectively.
The ward admission rate ratio from the ED was further
determined for patients who had a confirmed influenza diag-
nosis using either POCT or routine laboratory diagnostics. The
ratio associated with POCT vs a laboratory-based result (obvi-
ously with longer turnaround time) was 0.72 (95% CI:
0.53e0.97; P ¼ 0.031). Availability of POCT did not affect total
admissions, total medical admissions, or waiting times for a
ward bed (Table I). There was no significant difference in 30-
day all-cause mortality rate or intensive care unit admission
rate for influenza-positive patients across all three influenza
seasons (Table II).
Discussion
POCT for influenza had an overall positive impact on hos-
pital operational management. The Abbott ID NOW assay
demonstrated satisfactory performance characteristics in
relation to practical implementation across two influenza
seasons. However, in the 2018e2019 influenza season (then
referring to the Alere i Influenza AþB test) there was a sig-
nificant issue with respect to false-positive results associated
with concurrent influenza A and B reporting. Chapin et al.
reported similar poor specificity for influenza A and B in their
study [9]. By the 2019e2020 season, the manufacturer had
been acquired and the new multinational company owner
resolved the poor performance characteristics of the assay.
Clearly, this issue highlights the requirement for awareness of
the limitations of individual assays, alongside vigilance
regarding aberrant results contradicting, or at odds with,
expected results. Indeed, adoption of new diagnostic tech-
nology should be complemented by quality assurance pro-
grammes that ensure appropriate standards of commissioning
and validation. In our hands, following resolution of this spe-
cific problem, the Abbott ID NOW Influenza A & B 2 demon-
strated acceptable sensitivity and specificity. Our observations
mirror those of Kanwar et al., who also reported reliablewait for a bed across the peak of three influenza seasonsa
dmitted Admitted medicine Wait for bed (h)
(66) [23.69] 33.77 (33) [13.07] 13.7 (13.5) [16.97]b
(60.5) [20.50] 33.44 (33) [14.07] 15.93 (14.7) [17.48]b
(56.5) [18.26] 29.44 (30) [11.36] 17.7 (14.7) [19.56]b
pected that data would reflect a positively skewed distribution.
Table II
Comparison of patients who had a point-of-care test (POCT) or had influenza across the three influenza seasons
Variable 2017e2018 2018e2019 2019e2020
Total POCT 504 685
Age, median (IQR) Not applicable 59 (40e74) 68 (49e79)
Sex
Male 238 (47.3%) 334 (48.7%)
Female 266 (52.7%) 351 (51.3%)




POCT result 120 136
Age, median (IQR) 49 (37e67) 64 (31e78)
Male Not applicable 60 (50%) 64 (47.1%)
Female 60 (50%) 72 (52.9%)
Laboratory result 402 193 199
Age, median (IQR) 68 (49e78) 59 (41e76) 66 (39e78)
Male 187 (46.5%) 89 (46.1%) 81 (40.7%)
Female 215 (53.5%) 104 (53.9%) 119 (59.3%)
Influenza A (total) 149 313 290
Age, median (IQR) 64 (44e76) 54 (39e72) 67 (42e79)
Male 72 (48.3%) 149 (47.6%) 123 (42.4%)
Female 77 (51.7%) 164 (52.4%) 167 (57.6%)
Influenza B (total) 253 0 45
Age, median (IQR) 70 (53e80) Not applicable 34 (27e62)
Male 115 (45.5%) Not applicable 22 (48.9%)
Female 138 (54.5%) Not applicable 23 (51.1%)
30-day all-cause mortality 11 (2.7%) 13 (4.2%) 14 (4.2%)
30-day ICU admission 7 (1.7%) 7 (2.2%) 7 (2.1%)
IQR, interquartile range; ICU, intensive care unit.
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influenza diagnosis in children [7].
By contrast with Kanwar et al., our focus was on assessment
of POCT to detect influenza when presenting at the ED and,
specifically, the impact of POCT on patient flow in a crowded
ED. An absolute reduction in numbers of healthcare-associated
influenza between the pre- and post-implementation periods
was observed. The ability to expedite allocation of confirmed
influenza cases into isolation rooms within the ED while
awaiting an isolation or cohort bed on the ward was the clinical
focus for implementation of POCT; the objective was reduced
cross-transmission within the department. In short, our findings
suggest that early availability of influenza results can reduce
healthcare-associated infections across the hospital. Similar
reduction in cases of influenza diagnosed after 72 h of admis-
sion was observed by Garvey et al. when POCT was adopted in
an acute medical assessment unit in a large teaching hospital
[26]. In general, influenza-positive patients are cohorted into
small bedded areas as part of routine infection prevention and
control practice but, in our situation, a cohort ward dedicated
to influenza was not available in any season. Therefore, it is
reasonable to conclude that the observed reduction of
healthcare-associated influenza was due to a reduction of
transmission within the ED that was enabled by readily avail-
able POCT results, informing appropriate bed placement. We
are confident in this observation as we did not see a significant
variation in ED presentations across the three relevant influ-
enza seasons and, in fact, although waiting times for an inpa-
tient bed for 2018e2019 and 2019e2020 would most likely haveincreased the risk of healthcare-associated infections, we
noted decreased incidences. This was itself interesting despite
the elongated influenza season peak in 2017e2018 and the
2017e2018 vaccine mismatch, with poor coverage for the
influenza B/Yamagata lineage circulating, which at least par-
tially explains the relatively high influenza B activity during
that influenza season [23].
In our setting, once POCT had been established, a lower
admission rate was observed for patients presenting to hospital
with suspected influenza. This is consistent with other studies
suggesting that timely POCT results e even with sensitivities
inferior to laboratory testinge can assist with clinical decision-
making, albeit not necessarily in the ED [13,27,28]. The SARS-
CoV-2 (COVID-19) pandemic has kindled interest in timely
diagnostics to differentiate viral respiratory infections with
similar clinical presentations. Whereas sensitivity of >90% for
influenza appears sufficient for reduction of healthcare-
associated influenza outbreaks in our study, it may be insuffi-
cient for COVID-19. An Abbott ID NOW COVID-19 test is now
available as a POCT for COVID-19. An initial study reported poor
sensitivity, although a sponsored clinical study described 95%
sensitivity and 97.9% specificity within seven days of symptom
onset [29,30]. Mina et al., however, argued that consideration
of the sensitivity and specificity alone should not dictate the
adoption of a PCR assay [31]. In that context, our observations
suggest that balance between sensitivity and the rapidity of
results may result in positive clinical impact. It is likely, how-
ever, that the COVID-19 pandemic has reduced utility of
influenza-only POCTand that emphasis would more valuably be
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SARS-CoV-2 and influenza A or B.
The limitations of our study relate to its retrospective
design, and therefore that a causal relationship could not be
confirmed between implementation of POCT and admission
rate ratio or reduction in healthcare-associated influenza
cases. Only 18 influenza B cases were detected using POCT,
correlating with patterns observed in national data. Thus, the
sensitivity and positive predictive value for influenza B cannot
be defined, and may not be reliable in seasons when influenza B
may be dominant. Further, due to the lack of electronic patient
or prescribing records, the impact of POCT on antimicrobial
prescribing for patients with confirmed influenza was not pos-
sible. Notably, prescriptions of oseltamivir were not studied.
Finally, cost-analysis of the benefits of POCT was not per-
formed as bed capacity during influenza season operates
beyond 100% in our hospital group, and impact of reduction in
admissions due to influenza cases cannot be determined spe-
cifically. However, indirect savings due to reduction in
healthcare-associated influenza cases or outbreaks were likely
achieved.
In conclusion, the adoption of POCT for influenza virus in the
ED was a success in its diagnostic utility and infection control
purpose. A user-friendly, easily operable POCT device, with
rapid results for virus infection available directly to clinical
staff, assisted in clinical decision-making and allowed appro-
priate isolation of patients with influenza. This resulted
directly in associated reduction in hospital-acquired influenza
infection.
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